M
Michael Clearfield
Researcher at Touro University California
Publications - 86
Citations - 16178
Michael Clearfield is an academic researcher from Touro University California. The author has contributed to research in topics: Myocardial infarction & National Cholesterol Education Program. The author has an hindex of 30, co-authored 85 publications receiving 15013 citations. Previous affiliations of Michael Clearfield include Harvard University & University of North Texas Health Science Center.
Papers
More filters
Journal Article
The National Cholesterol Education Program Adult Treatment Panel III guidelines
TL;DR: The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) set of guidelines provides physicians with evidence-based recommendations on the classification, diagnosis, and treatment of lipid disorders, and the impact of ATP III on osteopathic physicians is reviewed.
Journal ArticleDOI
Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy.
TL;DR: An awareness of the benefits of appropriate statin treatment, and evidence showing that they can be safely added to hormone replacement therapy prescribed for the relief of menopausal symptoms and osteoporosis, provides the opportunity to optimize clinical outcomes for coronary heart disease among the large and expanding population of postmenopausal women.
Journal Article
The efficacy of gemfibrozil therapy for raising high density lipoprotein levels.
TL;DR: It is concluded that gemfibrozil is most effective in reducing serum triglycerides, LDL-C and increasing serum HDL-cholesterol in HTG patients who also have comparatively high initial LDL cholesterol levels (Fredrickson's type IIb phenotype).
Journal ArticleDOI
Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort
TL;DR: In the enrollment phase of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a number of heart disease-free potential subjects did not qualify to participate in the study because their low-density lipoprotein cholesterol (LDL-C) levels fluctuated as mentioned in this paper.
Journal Article
Adult Treatment Panel III: do we really need another set of cholesterol guidelines?
TL;DR: The LDL-C goal of less than 100 mg/dL for those with coronary heart disease (CHD) is now extended to patients with diabetes and those with a Framingham risk score of greater than 20% in 10 years, both of which are now considered "CHD risk equivalents".